keyword
MENU ▼
Read by QxMD icon Read
search

Exalgo

keyword
https://www.readbyqxmd.com/read/22795050/safety-and-tolerability-of-once-daily-oros-%C3%A2-hydromorphone-extended-release-in-opioid-tolerant-adults-with-moderate-to-severe-chronic-cancer-and-noncancer-pain-pooled-analysis-of-11-clinical-studies
#1
Srinivas R Nalamachu, Michael Kutch, Martin E Hale
CONTEXT: The efficacy and tolerability of once-daily hydromorphone extended release (ER) (OROS(®) hydromorphone ER, Exalgo(®), Mallinckrodt Brand Pharmaceuticals, Inc., Hazelwood, MO) in patients with chronic cancer and noncancer pain have been reported in previous studies. OBJECTIVES: The objective of this analysis was to assess the pooled safety data of OROS hydromorphone ER in opioid-tolerant patients with chronic cancer and noncancer pain. METHODS: Safety results were pooled from 11 clinical studies in opioid-tolerant patients: one 12-week, double-blind, placebo-controlled study; three active-controlled studies; and seven uncontrolled studies (durations of three to 52 weeks)...
December 2012: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/21836545/extended-release-hydromorphone-exalgo-for-pain
#2
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
August 25, 2011: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"